NYSE:JNJPharmaceuticals
Johnson & Johnson (JNJ) Enters U.S. Robotic Surgery With FDA Cleared OTTAVA
Johnson & Johnson (NYSE:JNJ) has received De Novo classification and marketing authorization from the FDA for its OTTAVA Robotic Surgical System.
OTTAVA is described as the world's first table integrated soft tissue robotic platform cleared for multiple general surgery procedures in the U.S.
This authorization marks Johnson & Johnson's formal entry into the U.S. robotic surgery market alongside established competitors.
Johnson & Johnson enters this development phase with its stock at...